

Improving CT scan for lung cancer diagnosis with an integromic signature

SUPPLEMENTARY FILES

Table S1. Biomarkers relative to patient smoking (pack-years)

Biomarkers	Coefficients	P-value
Plasma-miRN-205	-0.208	0.023
Sputum miRNA-210	-0.195	0.011
Sputum lncRNA-SNHG1	-0.244	0.027
Sputum lncRNA-H19	-0.162	0.040
Sputum snoRD66	-0.200	0.012
Sputum lncRNA-HOTAIR	0.220	0.016
Sputum DNA methylation, RASSF1A	0.233	0.029
Sputum Veillonella	0.244	0.018

Table S2. Biomarkers relative to patient gender

Biomarkers	Coefficients	P-value
Sputum miRNA-31	0.218	0.015
lncRNA0-SNHG1	0.126	0.028
Sputum miR-126	0.164	0.037

Table S3. Biomarkers relative to patient race

Biomarkers	Coefficients	P-value
Sputum snoRD78	0.148	0.035
Sputum snoRD66	0.129	0.043

Table S4. Biomarkers relative to patient COPD

Biomarkers	Coefficients	P-value
Sputum lncRNA-SNHG1	0.231	0.001
Sputum lncRNA-H19	0.186	0.014
Sputum lncRNA-HOTAIR	0.201	0.002
Sputum snoRD66	0.164	0.021
Plasma lncRNA0-RMRP	0.276	0.006
Sputum DNA methylation, RASSF1A	0.363	0.010
Sputum bacterial biomarker, Acidovorax	0.320	0.002

COPD: Chronic obstructive pulmonary disease.

Table S5. Clinical and radiological features relative to patient diagnosis (cancer vs. normal)

Biomarkers	Coefficients	P-value
Smoking pack-years	0.177	0.025
Diameter of the PNs	0.249	0.001
Spiculation of the PNs	0.131	0.038
Upper lobe location of the PNs	0.148	0.036

PNs: Pulmonary nodules.

Table S6. Diagnostics of the integromic signature for lung cancer detection in PNs with different sizes (≥ 20 mm vs. < 20 mm)

Performance	A training set		A validation set	
	In PNs with ≥ 20 mm (%)	In PNs with < 20 mm (%)	In PNs with ≥ 20 mm (%)	In PNs with < 20 mm (%)
Sensitivity (95% CI)	90.28 (80.99–93.93)	85.42 (72.24–90.16)	88.89 (65.29–98.62)	83.33 (51.25–97.91)
Specificity (95% CI)	95.97 (90.84–98.68)	91.03 (82.23–96.32)	94.74 (73.97–99.87)	90.32 (74.25–97.96)

PNs: Pulmonary nodules; CI: Confidence interval.